of these complexes were detected after activation of a Cterminal deletion mutant of G-CSF-R that lacked all four conserved cytoplasmic tyrosine residues. G-CSF induced formation of Syp/GRBZ complexes in all the tyrosine-substitution mutants, suggesting that this association did not depend on the presence of single specific tyrosine residues in G-CSF-R. In contrast, tyrosine 764 of G-CSF-R appeared to be exclusively required for tyrosine phosphorylation of She and its association with p145 and GRB2. In addition, tyrosine 764 also specifically mediated binding of GRB2 to p90 without the involvement of Shc. These findings indicate that tyrosine 764 of G-CSF-R has a prominent role in G-CSF signal transduction.
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Recent studies have shown that binding of G-CSF to its receptor results in rapid phosphorylation of tyrosines of the receptor protein itselfI3.l4 and of the Janus kinases, Jakl l4. l5 and Jak2. '5,'6 The cytoplasmic tyrosine kinases, Lyn and Syk, have also been suggested to play a role in G-CSF-R signal transd~ction.'~ Phosphorylated tyrosine residues form potential binding sites for cellular Src homology 2 (SH2) domain-containing signaling molecules." The specificity of these interactions is determined by the abilities of different SH2 domains to recognize different sequences surrounding the phosphorylated t y r o~i n e . "~~~ SH2 domains have been identified in a wide variety of molecules, including those with enzymatic activity, such as Src family tyrosine kinases, p21R" GTPaseactivating protein:' phospholipase Cy,'' phosphotyrosine phosphatases (HCPIPTPlC and Syp/PTP1D), [23] [24] [25] 26 and those with no obvious enzymatic activity, including Shc? GRB2:' Crk,29 and N c~.~' The SH2 domain-containing proteins with no apparent enzymatic activity are believed to act as adapter molecules, linking phosphorylated receptors to downstream effectors. For instance, Shc and GRB2 function as adapter proteins in the p2lRns/mitogenactivated protein (MAP) kinase signal transduction pathvariety of receptors, providing a binding site for the SH2 domain of GRB2.33 GRB2 can be bound to the p21R" guanine nucleotide exchange factor, son of sevenless (SOS).'~~'' Translocation of SOS to the plasma membrane, leading to activation of p2lRUs, can be mediated either by direct binding of GRB2 to the phosphorylated re~epto?~' or via involvement of tyrosine-phosphorylated S~C~' . '~ or S~P .~~. " The human G-CSF-R cytoplasmic domain contains four tyrosine residues, located at positions 704, 729, 744, and 764. To establish the role of each of these tyrosines in G-CSF signaling, we individually replaced these residues with phenylalanine using a polymerase chain reaction (PCR)-based mutation strategy. We show that activation of wild type (WT) G-CSF-R induces rapid tyrosine phosphorylation of Shc and association of Shc with GRB2. phosphorylation of Shc. Activation of Shc is accompanied by tyrosine phosphorylation and association of 145-kD proteins of unknown identity, resulting in the formation of p149 Shc/GRB2 complexes. Tyrosine 764 is also predominantly involved in the phosphorylation of 90-kD proteins that form complexes with GRB2. Finally, we demonstrate that the Cterminal domain of activated G-CSF-R mediates binding of G m 2 to tyrosine-phosphorylated Syp. In contrast to the formation of pl45/Shc/GRB2 or p90/GRB2 complexes, Syp/ GRB2 binding is not mainly accomplished via one tyrosine residue of G-CSF-R.
MATERIALS AND METHODS
Site-directed mutagenesis. Human G-CSF-R cDNA was cloned in the pBluescript vector (pBS) and in the eukaryotic expression vector PLNCX,'~ as described previously." PCR techniques were used to individually substitute the four tyrosine residues located in the cytoplasmic domain of G-CSF-R for phenylalanine residues (Fig  l) , according to a recently described method for site-directed mutagenesis." The oligonucleotides 5'-CAGACCTITGTGCTG-CAGGG-3' (Y704F, containing a silent PstI site), 5"GATCAA-GTACTITTTGGGCAGCT-3' (Y729F, containing a silent ScaI site), 5'-GGGCACTITCTCCGCTGTGAC-3' (Y744F), and 5'-AGCCCCAAAAGCTITGAGAACCT-3' (Y764F, containing a silent Hindm site) were designed as mutagenic primers. The human G-CSF-R cDNA cloned in pBS was used as the template in the first PCR, with a mutagenic primer and with primer M13-20 (5'-GTAAAACGACGGCCAGT-3'), a universal primer specific for pBS. In the second PCR, the human G-CSF-R cDNA cloned in pLNCX was used as the template, with the product of the first PCR as a megaprimer and with primers M13-20 and FR2 (5'-TGTGAT-CATCGTGACTCCCTT-3'). The PCR products were cloned in pLNCX. All mutations were confirmed by nucleotide sequencing. Deletion mutants DA and M1 have been described previously."
Cells and transfection. The L-3-dependent murine pro-B cell line, BAF3;' was maintained in RPMI 1640 medium supplemented with 10% fetal calf serum and 10 ng murine IL-3 per milliliter.
Transfection of BAF3 cells was performed by electroporation. Following gene transfer, cells were cultured in IL-3-containing medium for 24 hours and then selected in G418 (Gibco-BRL, Breda, The Netherlands) at a concentration of 1.5 mg/mL. Multiple clones were expanded for further analysis. Reverse transcriptase-PCR using the primers FRh4l (5'-CTGCTGTI'GTTAACCTGCCTC-3') and RV25.1 (5'-GTAGATCTI'AGTCATGGGC'ITATGG-3') was performed to check the proper expression of WT and mutant G-CSF-R constructs. The products were either digested by PstI (Y704F). ScaI (Y729F), and HindIII (Y764F) or sequenced following cloning in pBS (Y744F). To detect G-CSF-R proteins on the cell surface, cells were treated for 30 minutes at 4°C with rabbit anti-human G-CSF-R antibody 1729 (1:lOO dilution; raised against amino acids 17 to 344 in the extracellular domain of the receptor). After washing, cells were incubated for 30 minutes at 4°C with a 1:40 dilution of fluorescein-conjugated goat-anti-rabbit IgG (Nordic Immunology, Tilburg, The Netherlands). Samples were analyzed by flow cytometry using a FACSCAN (Becton Dickinson, San Jose, CA).
DNA synthesis assay. DNA synthesis was assayed by ['HIthymidine (3H-TdR) uptake, as described previously." Briefly, cells (1 X 10") were incubated in triplicate in 100 pL 10% fetal calf serum-RPM1 medium supplemented with titrated concentrations of human G-CSF or murine IL-3 in 96-well plates for 48 hours. Eight hours before cell harvesting, 0.1 pCi 'H-TdR (2 Ci/mmol/L; Amersham International, Amersham, UK) was added to each well. 'HTdR incorporation was measured by liquid scintillation counting.
Preparation of cell lysates, immunoprecipitation, and Western blotting. Before stimulation, cells were deprived of serum and factors for 10 hours at 37°C in RPMI 1640 medium. One hour before addition of growth factors, 10 pmol/L sodium orthovanadate (Na3V04) was added. Cells (5 X 106/mL) were incubated in RPMI 1640 medium in the presence of human G-CSF (100 ng/mL) or murine IL-3 (1 pg/mL) for 1 to 30 minutes at 37°C or without factors (control). At the different time points, 10 v01 ice-cold phosphatebuffered saline and 10 pmoVL Na3V04 were added. Subsequently, cells were centrifuged and lysed by incubation for 1 hour at 4°C in lysis buffer (20 mmoVL Tris hydrochloride, pH 8.0, 137 mmol/L NaCl, 10 mmoVL EDTA, 100 mmoVL NaF, 1% Nonidet P-40, 10%
For personal use only. on November 11, 2017 . by guest www.bloodjournal.org glycerol, 2 mmoVL Na3V04, 1 mmol/L Pefabloc SC, 50 pg/mL aprotinin, 50 pg/mL leupeptin, 50 pg/mL bacitracin, and 50 pg/mL iodoacetamide). Insoluble materials were removed by centrifugation for 30 minutes at 10,000 X g at 4°C. Immunoprecipitations were performed essentially as previously described. 16 In brief, supernatants of the clarified cell lysates were incubated overnight at 4°C with either anti-Shc3' or anti-GRB2 (Santa CNZ Biotechnology Inc, Santa Cruz, CA) antibodies. Protein A-Sepharose beads (Pharmacia, Uppsala, Sweden) were then added for 1 hour at 4°C. After washing the beads with ice-cold lysis buffer five times, bound proteins were eluted by boiling for 5 minutes in sodium dodecyl sulfate (SDS) sample buffer. Following SDS-polyacrylamide gel electrophoresis (SDS-PAGE), proteins were electroblotted onto nitrocellulose (0.2 pm; Schleicher & Schuell, Dassel, Germany). Filters were blocked by incubation in 0.3% Tween 20 in Tris-buffered saline ([TBS] 10 mmoVL Tris hydrochloride, pH 7.4, and 150 mmoVL NaCI) for 1 hour at 37"C, washed in TBST (0.05% Tween 20 in TBS), and incubated with antibodies diluted in TBST. Antibodies used for Western blotting were antiphosphotyrosine antibody 44310 (Upstate Biotechnology Inc, Lake Placid, NY), anti-Shc, anti-GRB2, and antiSyp (Santa Cruz). After washing with TBST, immune complexes were detected with horseradish peroxidase-conjugated species-specific antiserum (DAKO, Glostrup, Denmark), followed by enhanced chemiluminescence reaction (DuPont, Boston, MA). In some instances, membranes were stripped in 62.5 mmol/L Tris hydrochloride, pH 6.7, 2% SDS, and 100 mmoVL P-mercaptoethanol at 50°C for 30 minutes, reblocked, washed, and reprobed.
Glutathione S-transferasdGRB2 capture. Cell lysates, prepared as described earlier, were incubated for 2 hours at 4°C with 2 pg glutathione S-transferase (GST)/GRB2 fusion protein3' bound to glutathione-Sepharose beads (Pharmacia). After washing the loaded beads in ice-cold lysis buffer five times, bound proteins were eluted by boiling for 5 minutes in SDS sample buffer, separated by SDS-PAGE, and analyzed by Western blotting, as described earlier.
RESULTS

Expression of and mitogenic signaling by different forms of G-CSF-R.
To determine expression levels of mutated G-CSF-R proteins as compared with WT proteins in BAF3 transfectants, cells were stained with anti-human G-CSF-R antibodies and analyzed by flow cytometry.
Examples of clones expressing WT or mutant G-CSF-R proteins are shown in Fig 2. The abilities of transfectants to proliferate in response to G-CSF were examined in 3H-TdR uptake assays. G-CSF responses of BAF3 cells expressing the tyrosine-to-phenylalanine substitution mutants were comparable to responses of BAF3 cells expressing WT G-CSF-R (Fig 3) . Repeated analyses of at least three independent clones of each mutant gave identical results. G-CSF-R levels and G-CSF responses of BAF3 cells expressing deletion mutants M1 and DA have been described previously and were essentially similar to those of BAF3 cells expressing WT G-CSF-R." (Fig 4A and  B) . Reprobing of the blot with anti-Shc antibodies confirmed equal loading of the samples (Fig 4C) and showed that the 145-kD proteins were not recognized on Western blots by anti-Shc antibodies, and thus co-precipitated in activation of Shc, BAF3 transfectants expressing C-termim nal deletion or substitution mutants of G-CSF-R (Fig 1) were   3 studied. G-CSF-stimulated tyrosine phosphorylation of Shc (Fig 5A and B) . In contrast, no activation of Shc and .-0 tants M 1 and DA, despite the equal presence of Shc proteins as compared with WT G-CSF-R transfectants (Fig 5C) . In parallel control incubations, IL-3 induced tyrosine phosphorylation of Shc and p145 in all of these transfectants. Repeated analyses of at least three independent clones of each mutant gave identical results. were probed with anti-PY antibodies (Fig 6A) . Following 3. L 3 has previously been shown to induce tyrosine phosphorylation of S~C.~*"' Phosphorylation of Shc was induced following stimulation with G-CSF and IL-3 ( Fig 4A) . Of three Shc isoforms, ie, ~46'~', ~5 2 '~, and p66sk, that have been described?' ~5 2 '~ was predominantly phosphorylated. Only minimal activation of ~4 6 '~ was seen, whereas ~6 6 '~ is not present at detectable levels in BAF3 cells (Fig 4C) . Upon stimulation with G-CSF, tyrosine phosphorylation of Shc was induced within 1 minute, reached a maximum at 5 minutes, and declined after 10 minutes. Tyrosine-phosphorylated proteins of approximately 145 kD (p145) co-immunoprecipitated with tyrosine-phosphorylated Shc after G-CSF and IL-3 treatincubation with G-CSF and IL-3, tyrosine-phosphorylated proteins of approximately 52,70,90, and 145 kD co-precipitated with GRB2. The kinetics of G-CSF-stimulated association of GRB2 with tyrosine-phosphorylated 52-and 145-kD proteins were comparable to the kinetics of tyrosine phosphorylation of Shc and its association with p145, as seen in anti-Shc immunoprecipitates (Fig 4A and B) . The somewhat lower reactivity of p145 with anti-PY antibodies observed after 5 minutes of stimulation with G-CSF was not confirmed in repeated experiments. Reprobing of the blot with anti-Shc antibodies identified the 52-kD protein as Shc (Fig 6B) . Upon G-CSF stimulation, tyrosine phosphorylation of 70-kD proteins occurred within 1 minute and persisted for at least 30 minutes. Reprobing the blot revealed that a subfraction of the 70-kD proteins reacted with anti-Syp (Fig 6C) . Essentially similar results were obtained using GST/GRB2 fusion proteins (Fig 7) .
G-CSF
G-CSF induces association
Mutation Y764F reduces G-CSF-induced association of GRB2 with tyrosine-phospho~lated Shc, 90-kD, and 145-kD proteins. Since G-CSF-R mutant Y764F failed to induce tyrosine phosphorylation of Shc and since GRB2 only associates with Shc in its tyrosine-phosphorylated form. anti-GRB2 immunoprecipitates from G-CSF-stimulated BAF3 cells expressing mutant Y764F should not contain Shc. As shown in Fig 8A, G-CSF stimulation only induced association of GRB2 with tyrosine-phosphorylated 70-kD proteins that partly hybridized with anti-Syp antibodies after reprobing (data not shown). The kinetics correspond to the kinetics seen in BAF3 cells expressing WT G-CSF-R. G-CSF stimulation did not induce association of GRB2 with phosphorylated Shc or with proteins of 145 kD, whereas in parallel control incubations, IL-3 stimulation did (Fig 8A  and B) . Although in the exposure presented the 145-kD proteins are not clearly visible after IL-3 stimulation, they were visible in longer exposures of the same blot (data not shown). In contrast to WT G-CSF-R, activation of mutant Y764F only marginally induced association of GRB2 with phosphorylated 90-kD proteins. 
IP: a-GRB2
A. blot: a -P Y The C-terminal region qf G-CSF-R is required for G-CSF-stimulated association of GRBZ with tyrosine-phosphorylated Syp. To determine whether the C-terminal region of G-CSF-R is involved in association of GRB2 with tyrosine-phosphorylated Syp, BAF3 transfectants expressing deletion and substitution mutants of G-CSF-R were studied. As expected, G-CSF-stimulated association of GRB2 with tyrosine-phosphorylated Shc was observed in cells expressing substitution mutants Y704F, Y729F, and Y744F, but not in cells expressing deletion mutants M1 and DA (Fig 9A) . Tyrosine-phosphorylated 70-and 90-kD proteins were associated with GRB2 after G-CSF stimulation of cells expressing substitution mutants Y704F. Y729F. and Y744F, but not deletion mutant M 1. These associations were severely reduced in cells expressing deletion mutant DA (Fig 9A) . After stripping and reprobing of the blot, part of the 70-kD proteins reacted with anti-Syp antibodies (data not shown). Repeated analyses of at least three independent clones of each mutant gave identical results.
DISCUSSION
Signaling from G-CSF-R involves at least two major routes, ie, the JaWSTAT and p2IR"'/MAP kinase path- -p52
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cule, Vav, with a molecular weight of 95 kD, has recently been shown to form complexes with GRB2." We therefore investigated whether the 90-kD proteins could be Vav. However, reprobing of blots with anti-Vav antibodies indicated that p90 is distinct from Vav. The phosphotyrosine phosphatase (PTP) Syp (synonymous with FTP-ID, PTP-2C, SH-PTP2, or SH-PTP3) has been implicated in signal transduction mediated by plateletderived growth factor (PDGF), epidermal growth factor (EGF), insulin, and the hematopoietic growth factors IL-3, GM-CSF, and IL-6.24.'5.49.s4.s5 Syp binds to activated PDGF-R and EGF-R via SH2 domains and is then tyrosine-phosp h~r y l a t e d .~~~'~~~~ Tyrosine phosphorylation of Syp enhances its catalytic activity." The spectrum of activities of Syp has not been fully elucidated. It has been suggested that Syp acts as a negative regulator of receptor signal transduction by dephosphorylation of receptors, similar to the structurally related hematopoietic cell phosphatase (HCP)." However, in apparent contrast with this idea, Syp does not efficiently dephosphorylate EGF-R or PDGF-R.IS Alternatively, Syp could act as a positive regulator by dephosphorylating inhibitory phosphotyrosine sites. Recently, a novel function was attributed to Syp when it was discovered that tyrosine-phosphorylated Syp functions as an adapter between PDGF-R and GRB2,36.3x resulting in recruitment of the GRB2/Sos complex to the PDGFWSyp complex followed by activation of the p2IR" pathway." Our results suggest that Syp may have a similar role in G-CSF-mediated signal transduction.
G-CSF-induced Syp/GRB2 association was severely reduced in cells expressing C-terminal deletion mutant DA (containing only tyrosine 704) and was not detected in cells expressing deletion mutant M I (lacking all cytoplasmic tyrosines). These findings established that the C-terminal region of G-CSF-R is required for association of GRB2 with activated Syp. However, in contrast to the formation of p145/ Shc/GRB2 and p90/GRB2 complexes, G-CSF-induced Syp/ GRB2 association did not predominantly depend on the presence of one particular tyrosine residue of G-CSF-R. This was evident from the observation that all tyrosine-to-phenylalanine substitution mutants of G-CSF-R were capable of inducing Syp/GRB2 complexes. Assuming that, in analogy with PDGF-R, Syp acts as an adapter between G-CSF-R and GRB2, the association is partly induced via tyrosine 704 and partly via other tyrosine(s). Because GRB2 immunoprecipitates of cells expressing mutant Y764F contained tyrosinephosphorylated Syp but not the 90-and 145-kD proteins, the latter molecules are probably upstream of GRB2 in the signaling route, unless Syp would efficiently dephosphorylate the 90-and/or 145-kD proteins or interfere with their binding to GRB2.
Collectively, our data could fit into a model in which recruitment of GRB2 to G-CSF-R occurs via multiple mechanisms, two of which depend on the presence of tyrosine 764 of G-CSF-R. Signaling via phosphotyrosine 764 of G-CSF-R is achieved through phosphorylation of either 145-kD or 90-kD proteins. In the first mechanism, phosphorylation of 145-kD proteins provides a binding site for the SH2 or PTB domain of Shc. Shc is subsequently tyrosine-phosphorylated and becomes associated with GRB2. In the second mechanism, phosphorylated 90-kD proteins directly bind to GRB2 without the involvement of Shc. In the third mechanism, cytoplasmic phosphotyrosines of G-CSF-R bind Syp, which subsequently becomes tyrosine-phosphorylated, thereby providing a binding site for GRB2. Finally, a fourth possibility that still needs to be experimentally addressed is that GRB2 may bind directly to tyrosine residues of G-CSF-R.
The physiologic significance of the different signaling mechanisms of G-CSF-R involving GRE32 remains to be established. It is anticipated that activation of the p2IR" pathway may occur via all these different mechanisms, involving multiple tyrosines of G-CSF-R. This would fit with the observation that a C-terminal truncation mutant of G-CSF-R, lacking tyrosine 764, is still capable of activation of p2IR" and MAP kinase." Activation of the p21 RasA4AP kinase pathway by IL-3/GM-CSF receptors has recently been shown to be essential for supporting the survival of cells by preventing apopt~sis.'~ It is likely that activation of this route through G-CSF-R serves a similar goal. Full understanding of the specific role of tyrosine 764 of G-CSF-R in signaling awaits elucidation of the identity and function of p90 and p145 proteins.
